The share of HIV-positive tuberculosis patients on antiretroviral therapy in Mexico showed significant growth from 42 units in 2013 to 100 units in 2016, followed by fluctuations, and reaching 81 units in 2023. This indicates an upward trend overall, with some variances. Over the last two years, there was a year-on-year increase of about 3.9% and 2.6%, respectively, from 2021 to 2023.

Future trends to watch for:

Maintaining steady growth with forecast data predicting a continuous increase to 91 units by 2028.
The forecasted 5-year CAGR is projected at 1.86%, signifying moderate but stable growth.
A cumulative 5-year growth rate of 9.64% suggests a focused improvement in treatment coverage.